Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,845.00-1.52%ETH$2,446.04-0.38%GOLD$4,357.90-1.12%OIL$104.00+1.48%
Smart Investors Daily
AA

NASDAQ · AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

Healthcare · Biotechnology

$17.31

Down-$0.64 (-3.70%)

Updated Sep 10, 2026, 10:10 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.23B
P/E ratio
-12.12
Dividend yield
0.00%
52-week range
$16.23 – $42.48
Volume
1.64K
Avg. volume
3.2K

Price performance

AAPG price history

1M range · 19 trading sessions · Daily adjusted prices

AAPG closed at $17.31 after 19 trading sessions, down 8.75% for the selected period.

Last close
$17.31
Period change
-8.75%
Period low
$16.23
Period high
$19.00
Daily close
View OHLC price history
AAPG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$17.23$17.33$17.22$17.311.64K
Sep 8, 2026$17.48$17.55$17.25$17.4420.9K
Sep 4, 2026$17.70$17.745$17.60$17.6155.1K
Sep 3, 2026$17.58$17.59$17.20$17.3610.09K
Sep 2, 2026$16.64$17.00$16.64$16.812.48K
Sep 1, 2026$16.84$16.84$16.23$16.237.07K
Aug 31, 2026$17.78$17.78$17.10$17.106.06K
Aug 28, 2026$17.92$18.2761$17.73$18.27616.35K
Aug 27, 2026$18.42$18.73$18.26$18.7315.62K
Aug 26, 2026$17.12$17.12$16.80$16.904.86K
Aug 25, 2026$17.00$17.12$16.79$16.793.35K
Aug 24, 2026$16.83$17.00$16.70$16.716.54K
Aug 21, 2026$17.15$17.4435$17.00$17.001.84K
Aug 20, 2026$17.99$17.99$16.80$17.3212.16K
Aug 19, 2026$18.1448$19.00$17.95$18.0323.12K
Aug 18, 2026$17.92$18.1991$17.40$18.19916.88K
Aug 17, 2026$18.30$18.4846$18.00$18.205.88K
Aug 13, 2026$19.17$19.19$18.985$19.002.98K
Aug 12, 2026$18.64$18.97$18.57$18.972.63K

Latest AAPG news

The latest Smart Investors Daily articles mentioning AAPG.

Stock researchCompany · Overview

AAPG research

Overview

Company profile and research snapshot.

Company profile

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$48.00
Implied upside
—
Analysts
13
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in four upcoming investor conferences in New York, New York. Citi’s 2026 Biopharm

Yahoo · Aug 28, 2026

Ascentage Pharma Group International (SEHK:6855) Could Be 18% Undervalued After Half Year Losses

Half year earnings put Ascentage Pharma Group International (SEHK:6855) losses in focus Ascentage Pharma Group International (SEHK:6855) released half year earnings to June 30, 2026, reporting sales of CNY 302.21 million and a net loss of CNY 816.69 million, with a basic loss per share of CNY 2.19. Ascentage Pharma Group International’s recent half year results arrived alongside a sharp move in the stock, with a 1 day share price return of 12.08% and a 7 day share price return of 9.88% at...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By